When we are mostly talking about neurodegenerative diseases, and in particular rare diseases such as MSA, it is not easy to see the big picture of ferroptosis, only "invented" 13 years ago as a new cell death method.
Diseases such as gestational diabetes mellitus, preeclampsia, preterm birth, and miscarriage can be regarded as ferroptosis diseases, but also many female cancers, and endometriosis, polycystic ovary syndrome, etc, can be classified as ferroptosis diseases.
ATH434 could one day be used in these diseases, who knows? It is a long way, but I cannot avoid thinking about this possibility. Some of them can be much easier to study than these slowly progressing neurodegenerative diseases. But ATH needs to find partners for these studies, many of them.The Role of Ferroptosis in Women's Health and Diseases
AffiliationsPMCID: PMC12356996 DOI: 10.1002/mco2.70296
- PMID: 40821694
Abstract
Currently, there are many diseases worldwide that seriously affect women's health. Among these, gestational disorders and female cancers such as ovarian cancer are particularly notable for their high morbidity and mortality rates. Over the past decade, ferroptosis, a distinct form of programmed cell death primarily driven by iron-dependent phospholipid peroxidation, has been implicated in the pathogenesis of various female-related diseases. Despite many studies individually reporting that ferroptosis plays a crucial pathogenic role in common female disorders, there has yet to be a systematic overview addressing the mechanisms linking ferroptosis with women's health and disease. Thus, we herein provide a comprehensive review of the relationship between cellular pathways of ferroptosis and women's health and disease and describe the current progress of targeted therapy for ferroptosis. Following a succinct introduction to the disease, we summarize the regulatory role of ferroptosis in women's health and its implications for disease progression, with the aim of facilitating a clearer understanding of the relationship between ferroptosis and women's health. Finally, we discuss the emerging challenges and opportunities presented by various agonists or inhibitors targeting ferroptosis as potential therapeutic strategies for female-related diseases, providing additional protective approaches contributing to female health.
Here is the full paper: https://onlinelibrary.wiley.com/doi/10.1002/mco2.70296
- Forums
- ASX - By Stock
- ATH
- Ferroptosis in women's health and diseases
ATH
alterity therapeutics limited
Add to My Watchlist
0.00%
!
1.3¢

Ferroptosis in women's health and diseases
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $119.6M |
Open | High | Low | Value | Volume |
1.3¢ | 1.4¢ | 1.3¢ | $6.295K | 481.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
58 | 23631783 | 1.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.4¢ | 14268786 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
57 | 23612553 | 0.013 |
30 | 18151483 | 0.012 |
13 | 5569965 | 0.011 |
22 | 12217700 | 0.010 |
12 | 4968127 | 0.009 |
Price($) | Vol. | No. |
---|---|---|
0.014 | 14268786 | 13 |
0.015 | 19191428 | 12 |
0.016 | 3455011 | 11 |
0.017 | 5708424 | 11 |
0.018 | 10460056 | 20 |
Last trade - 16.10pm 20/08/2025 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |
The Watchlist
RC1
REDCASTLE RESOURCES LIMITED
Ronald Miller, Non-Executive Director
Ronald Miller
Non-Executive Director
SPONSORED BY The Market Online